Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast ...

Johnson & Johnson (J&J) has announced that its bladder cancer therapy Balversa (erdafitinib) has been accepted by the ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...